NCT06717880招募中1 期
Phase I Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Wuhan Union Hospital, China1 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2023年7月28日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 260
- 试验地点
- 1
- 主要终点
- Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)
研究概览
简要总结
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign written informed consent and be able to comply with the program's visit schedule and related procedures.
- •Male or female subjects, age 18~75 years.
- •Histologically or cytologically confirmed advanced colorectal cancer.
- •Subjects who have progressed on standard therapy, who are unsuitable for standard therapy, who do not have standard therapy, or who have refused standard therapy.
- •Adequate organ function.
- •At least one measurable lesion (target lesion) per RECIST v1.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
- •Life expectancy of 3 months or more.
- •Female subjects of childbearing age or male subjects whose partners are female subjects of childbearing age agree to strictly adopt effective contraceptive measures throughout the entire treatment period and 6 months after the treatment period.
排除标准
- •Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug.
- •Active epileptic seizures or active central nervous system (CNS ) metastases and so on.
- •Clinically significant cardiovascular or cerebrovascular disease.
- •Interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-associated pneumonia, and radiation pneumonitis requiring steroid hormone or other therapy, as well as history of severe abnormal lung function or other forms of restrictive lung disease.
- •History of allergies, asthma, atopic dermatitis.
- •Subjects with large amounts of pleural effusion or ascites.
- •Active autoimmune disease requiring systemic therapy within 2 years prior to first dose.
- •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •Subjects with known or suspected hypersensitivity to the study drug and any excipients.
- •Subject has a prior history of significant toxicity associated with immune checkpoint inhibitor administration or Bevacizumab that requires permanent discontinuation.
- •Subjects with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with the exception of persistent Grade 2 alopecia, peripheral neuropathy and so on.
- •Active uncontrolled bleeding or known bleeding tendency.
- •Any major surgery within 4 weeks prior to the first dose of study drug.
- •Known positive Human Immunodeficiency Virus (HIV) test, active hepatitis B, hepatitis C (HCV), tuberculosis.
- •Severe/active/uncontrolled infection, infection requiring systemic intravenous antibiotic therapy, or unexplained fever within 2 weeks prior to the first dose of study drug.
- •Diagnosis of another malignancy within 5 years prior to the first dose, exceptions include radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ, as well as post-radical localized prostate cancer, and papillary thyroid cancer.
- •Presence of any disease, treatment or laboratory test abnormality, or history or current evidence of substance abuse that, in the judgment of the investigator, may compromise the safety of the subject, interfere with obtaining informed consent, affect subject compliance, or compromise the safety evaluation of the study drug.
研究组 & 干预措施
Cohort A
Experimental
IBI363 Combined with Bevacizumab in Subjects with Advanced Colorectal Cancer
干预措施: IBI363 combined with Bevacizumab (Drug)
Cohort B
Experimental
IBI363 Combined with Furuitinib in Subjects with Advanced Colorectal Cancer
干预措施: IBI363 + Furuitinib (Drug)
结局指标
主要结局
Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)
时间窗: Through out the study (up to 2 years)
Adverse events will be assessed by investigator(s) according to Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0).
次要结局
- Objective response rate (ORR)(Through out the study (up to 2 years))
- Time to response (TTR)(Through out the study (up to 2 years))
- disease control rate (DCR)(Through out the study (up to 2 years))
- Duration of response (DoR)(Through out the study (up to 2 years))
- Progression-free survival (PFS)(Through out the study (up to 2 years))
- Overall survival (OS)(Through out the study (up to 2 years))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver MetastasesColorectal CancerNCT01343901Hoffmann-La Roche210
终止
1 期
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal CarcinomatosisPeritoneal CarcinomatosisNCT04047771Sichuan Clover Biopharmaceuticals, Inc.10
招募中
1 期
Study of IBI363 in Patients with Advanced First-line Gastric CancerIBI363 + ChemotherapyNCT06610799Xiangdong Cheng40
已完成
1 期
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaMelanomaNCT00790010Dana-Farber Cancer Institute46
进行中（未招募）
1 期
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsSolid TumorNCT04606472Sichuan Baili Pharmaceutical Co., Ltd.60